Isocitrate Dehydrogenase (IDH) Inhibitors Market Secures Remarkable Valuation of US$39.16 Billion in 2033

Isocitrate Dehydrogenase (IDH) Inhibitors Market

The isotrate dehydrogenase (IDH) inhibitors market sales is predicted to expand from US$ 1.7 billion in 2022 to US$ 39.16 billion in 2033, with a compound annual growth rate (CAGR) of 33% from 2023 to 2033.

Additionally, the development of more potent and selective IDH inhibitors, as well as the expansion of their use into other cancer types, is expected to further contribute to the growth of the market. Bayer and Agios Pharmaceuticals are among the key players in the IDH inhibitors market, with their respective drugs BAY 1436032 and ivosidenib being approved by the US FDA for the treatment of IDH-mutated cancers. These drugs have shown promising results in clinical trials, including high response rates and extended survival in patients with AML.

The IDH inhibitors market is a rapidly growing field with significant potential for the treatment of several types of cancer. Continued research and development efforts, as well as the development of new drugs and treatment strategies, are expected to contribute to the growth of the market.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16847

Key Takeaways:

• The global Isocitrate dehydrogenase (IDH) inhibitors market is expected to grow with a 33% CAGR during 2023 to 2033.
• Oral route of administration is expected to hold 49% of the market share in 2023 for Isocitrate dehydrogenase (IDH) inhibitors market.
• North America is expected to possess 46% market share for Isocitrate dehydrogenase (IDH) inhibitors market in 2023.
• Europe Isocitrate dehydrogenase (IDH) inhibitors market size is expected to possess 43% market share in 2023.

“The development of combination therapies and alternative treatment strategies is being explored to further optimize the clinical benefit of IDH inhibitors. This, in turn, is fueling the growth of IDH inhibitors market.” states an FMI analyst

Competitive Landscape:

Key players in the isocitrate dehydrogenase (IDH) inhibitors market are Bayer, Agios Pharma, Daiichi Sankyo, Ohm Oncology, Celgene, Philogen S.p.A., Tragara, Aslan Pharmaceuticals, Pfizer, Inc. and Sun Pharmaceutical Industries Ltd.

• Bayer is collaborating with other pharmaceutical companies, such as Agios Pharmaceuticals, in the development of IDH inhibitors. The two companies have a joint development and commercialization agreement for ivosidenib (AG-120), an oral small molecule inhibitor of the mutated IDH1 enzyme, which has been approved by the US FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.
• Agios’ Pharma lead IDH inhibitor candidate is ivosidenib (AG-120), an oral small molecule inhibitor of the mutated IDH1 enzyme. Ivosidenib works by inhibiting the production of the oncometabolite 2-hydroxyglutarate (2-HG) and inducing differentiation of leukemia cells. Ivosidenib has been approved by the US FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.

Key Segments:

Type:

• IDH1 Mutant Medullary Malignant Tumor
• IDH2 Mutant Medullary Malignant Tumor
• Peptides
• Small Molecule
• Others

Molecule Types:

• Monoclonal Antibody
• Peptides
• Small Molecules
• Others

Route of Administration:

• Oral
• Parenteral
• Subcutaneous

Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-16847

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube